Skip to content

Severe ARDS: Generating Evidence

Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03021824
Acronym
SAGE
Enrollment
2400
Registered
2017-01-16
Start date
2016-10-01
Completion date
2017-04-30
Last updated
2020-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome, Acute Respiratory Failure, Acute Respiratory Failure With Hypoxia

Keywords

Acute Respiratory Distress Syndrome, ARDS, Acute Lung Injury, ALI, Mechanical Ventilation, Extracorporeal Membrane Oxygenation, Neuromuscular Blockade, Vasodilator Agents, Prone Position, ECMO, Acute Respiratory Failure

Brief summary

An assessment of early management of moderate-severe ARDS in the United States, including ventilator management and use of rescue therapy.

Detailed description

Approximately one-quarter of ARDS patients develop severe hypoxemia, which has been associated with mortality rates approximating 40-50%. The majority have been described to present with severe disease at baseline, suggesting an opportunity for early intervention. In addition, use of evidence-based practices in severe ARDS is highly variable and inconsistent; use of unproven treatment modalities is also frequently seen. Given the variability in treatment practices in severe ARDS, an understanding of the patient-level and institutional-level factors contributing to differences in therapeutic approach is needed in order to improve the quality and consistency of care given to these high-risk patients. SAGE is a multicenter, observational cohort study examining the patient-level and institutional characteristics associated with variability in management of patients with moderate to severe ARDS, factors associated with survival or need for adjuvant therapy, and variability in ventilator management of patients on extracorporeal membrane oxygenation. Findings from this observational study can subsequently be used to inform future interventional trial development.

Interventions

None listed

Sponsors

University of Michigan
CollaboratorOTHER
Duke University
CollaboratorOTHER
University of California, Los Angeles
CollaboratorOTHER
Montefiore Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age \> 18 years 2. Patients with acute respiratory failure requiring invasive mechanical ventilation via an endotracheal tube or tracheostomy with current or planned admission to the ICU 3. Moderate-severe ARDS as defined by fulfillment of all of the following within 48 hours: 1. Bilateral opacities detected on chest radiograph or CT, not fully explained by effusions, lung collapse, or nodules 2. Respiratory failure not fully explained by cardiac failure or fluid overload 3. PaO2/FiO2 ratio \< 150 with a minimum of 5 cmH20 PEEP

Exclusion criteria

There are no

Design outcomes

Primary

MeasureTime frame
Hospital Mortality28 Days
Use of Adjunctive Therapy28 Days

Secondary

MeasureTime frame
Ventilator-Free Days28 Days
ICU-Free Days28 Days
Organ Failure7 Days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026